Trial intelligence / Profile preview

Bosentan in Systemic Sclerosis with Ischemic Digital Ulcers (RAPIDS 2 OL)

NCT00319696Phase 3Completed

Sponsor
Actelion Pharmaceuticals Ltd
Start
Jul 2004
Primary completion
Jan 2009
Modality
Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01

Overview

A Phase 3 trial of bosentan in systemic sclerosis (SSc), digital ulcer (DU), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2004; status: completed.

02

Drugs

bosentan
03

Conditions

systemic sclerosis (SSc)digital ulcer (DU)

Beyond the preview

Go deeper on NCT00319696.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00319696.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call